US venture capital firm Venrock has added Camille Samuels and Doug Dooley to the investment team, both in the Palo Alto office.
As a Partner, Samuels will focus on biotech and consumer health, while expanding the firm’s focus to later stage healthcare companies. Formerly an entrepreneur, Dooley will focus on infrastructure technologies and cloud-centric software. In the past month, Dooley made his first Venrock investment and joined the board of a stealth startup in the security and cloud networking market.
“Camille and Doug are terrific additions to the Venrock team — talented, driven and great cultural fits,” said Bryan Roberts of Venrock. “As we maintain a steady focus ahead of the curve, we look for great people to help us explore and expand our efforts, continually augmenting the diversified investment philosophy that has contributed to our success.”
Previously, Samuels was a managing director at Versant Ventures where she invested in Achaogen, Kythera, and Novacardia, among others. Prior to Versant, she was responsible for business development at Tularik and also spent time at Genzyme, Millennium Predictive Medicine and LEK Consulting.
“I look forward to continuing to partner closely with entrepreneurs,” said Samuels. “The Venrock team shares a unified vision and collaborative approach, and I’m excited to be a part of the firm.”
Originally established as the venture capital arm of the Rockefeller family in 1969, Venrock portfolio companies have included Adify, Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Millennium Pharma, SlideShare and Tudou.
Copyright © 2014 AltAssets